LENSAR (NASDAQ:LNSR – Get Free Report) and Sintx Technologies (NASDAQ:SINT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Profitability
This table compares LENSAR and Sintx Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENSAR | -34.03% | -49.02% | -21.12% |
| Sintx Technologies | -358.79% | -140.68% | -78.29% |
Risk and Volatility
LENSAR has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Sintx Technologies has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENSAR | 0 | 0 | 1 | 0 | 3.00 |
| Sintx Technologies | 0 | 1 | 0 | 0 | 2.00 |
LENSAR presently has a consensus target price of $8.00, indicating a potential upside of 7.53%. Given LENSAR’s stronger consensus rating and higher probable upside, equities research analysts clearly believe LENSAR is more favorable than Sintx Technologies.
Valuation & Earnings
This table compares LENSAR and Sintx Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENSAR | $42.16 million | 2.05 | -$14.38 million | ($1.46) | -5.10 |
| Sintx Technologies | $2.63 million | 1.23 | -$8.26 million | ($50.56) | -0.09 |
Sintx Technologies has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
40.2% of LENSAR shares are owned by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are owned by institutional investors. 38.5% of LENSAR shares are owned by company insiders. Comparatively, 0.0% of Sintx Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
LENSAR beats Sintx Technologies on 11 of the 14 factors compared between the two stocks.
About LENSAR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
About Sintx Technologies
Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
